Ieni Antonio, Cardia Roberta, Pizzimenti Cristina, Zeppa Pio, Tuccari Giovanni
Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", Section of Pathology, University of Messina, 98125 Messina, Italy.
Department of Medicine and Surgery, University of Salerno, 84131 Salerno, Italy.
J Pers Med. 2020 Feb 21;10(1):10. doi: 10.3390/jpm10010010.
Human epidermal growth factor receptor-2 (HER2)-expression gastro-oesophageal adenocarcinomas (GEA) gained interest as an important target for therapy with trastuzumab. In the current review, we focused the current knowledge on HER2 status in dysplastic and neoplastic gastric conditions, analyzing the methodological procedures to identify HER2 expression/amplification, as well as the proposed scoring recommendations. One of the most relevant questions to evaluate the useful impact of HER2 status on therapeutic choice in GEAs is represented by the significant heterogeneity of HER2 protein and gene expression that may affect the targeted treatment selection. Future development of biotechnology will continue to evolve in order to offer more powerful detection systems for the assessment of HER2 status. Finally, liquid biopsy as well as mutation/amplification of several additional genes may furnish an early detection of secondary HER2 resistance mechanisms in GEAs with a better monitoring of the treatment response.
人表皮生长因子受体2（HER2）表达的胃食管腺癌（GEA）作为曲妥珠单抗治疗的重要靶点受到关注。在当前综述中，我们聚焦于发育异常和肿瘤性胃部疾病中HER2状态的现有知识，分析鉴定HER2表达/扩增的方法程序以及提出的评分建议。评估HER2状态对GEA治疗选择的有益影响时，最相关的问题之一是HER2蛋白和基因表达存在显著异质性，这可能会影响靶向治疗的选择。生物技术的未来发展将持续演进，以提供更强大的检测系统来评估HER2状态。最后，液体活检以及其他几个基因的突变/扩增可能有助于早期检测GEA中的继发性HER2耐药机制，并更好地监测治疗反应。
